New human model could speed up TB drug and vaccine testing
NCT ID NCT05592223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new method to evaluate tuberculosis (TB) drugs and vaccines in 20 healthy adults. Researchers used a harmless version of the TB bacteria (BCG) to see how the body fights it and how treatments work. The goal was to create a faster, safer way to test new TB treatments in early-stage human trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune profiling unlock the hidden stages of tuberculosis?
- Could inhaled TB drugs curb the spread of Drug-Resistant tuberculosis?
- Can new tests predict who will develop active TB?
- Could a 3-Month TB cocktail replace the standard 6-Month regimen?
- Could a simple blood test ensure the right TB dose for kids?
- Community-Driven TB screening aims to reach vulnerable immigrants